C0526 - Is the Mutational Landscape of Hepatocellular Adenoma Distinct in the Setting of Oral Contraceptive Use?

Monday, October 24, 2022

3:00 PM – 5:00 PM ET

Location: Crown Ballroom

Has Audio

Presenting Author(s)

Caitlyn J. Smith, BS

University of Missouri
Columbia, MO

Caitlyn J. Smith, BS, Keela R. Scott, MD, Deepthi Rao, MD
University of Missouri, Columbia, MO

Introduction: Hepatocellular adenomas (HCA) are benign tumors with possible complications of bleeding and malignant transformation. Oral contraceptive us in women of childbearing are most frequently associated with hepatocellular development. This study investigates the multifactorial role of oral contraceptive use and its effect on mutation frequency, mutation count, and nodule size in patients with HCA.

Methods: Using the cBioPortal platform and systematic bioinformatical analysis of the Cancer Genome Atlas (INSERM) Cancer Cell 2014 data for hepatocellular adenoma, 30 HCA patients were included in this study. Of which twenty-one patients had used oral contraception for greater than two years, four patients < 2 years, and five patients had no reported history of oral contraceptive use.

Results: The mutational landscape of the lack of oral contraceptive use associated with HCA was distinct with statistically significant alterations in ACY1, APOA1, APOB, ARHGAP22, ARNTL2, BICRAL, C3ORF70, CASR, CD247, CDH9 mutation frequency (See Figure). Further, the mutation count was statistically significant as patients with oral contraceptive use < 2 years had the lowest mutation count of 6, (See Table). Additionally, the nodule size (mm) in patients with HCA was statistically significant as patients with a history of oral contraceptive use < 2 years had the smallest median nodule size of 37.5 mm (See Table).

Discussion: The findings in this study highlight the complex multifactorial role of oral contraceptive use in HCA. Further studies are essential for understanding the molecular and pathophysiologic impact of oral contraceptive use on functions of critical genes that exert carcinogenic potential.

Figure: The mutational landscape among oral contraceptive use in hepatocellular adenoma.

	No OCP use	OCP < 2 years	OCP use > 2 years	P-value
Mutation count	19	6	11	0.03
Nodule size (mm)	70 mm	37.5 mm	70 mm	0.03

Table: Mutation count and nodule size in hepatocellular adenoma with relation to oral contraceptive use.

Disclosures:

Caitlyn Smith indicated no relevant financial relationships.

Keela Scott indicated no relevant financial relationships.

Deepthi Rao indicated no relevant financial relationships.

Caitlyn J. Smith, BS, Keela R. Scott, MD, Deepthi Rao, MD. C0526 - Is the Mutational Landscape of Hepatocellular Adenoma Distinct in the Setting of Oral Contraceptive Use?, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.